| payload |
{"created_at":"2026-04-07T23:23:54.391 {"created_at":"2026-04-07T23:23:54.391414+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:2c8e736b9c003f36","evidence_event_ids":["evt_6459202eb177"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000148.txt","as_of":"2026-04-07T23:23:54.391414+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000148.txt","company":"Cartesian Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000148.txt","article_chars":2572,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_2bb6326d66bd3b6d","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000148.txt","content_type":"text/plain","enriched_at":"2026-04-07T23:55:58.448348+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000148.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000148.txt","source_event_id":"evt_6459202eb177","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"fc8a3a1760684932","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-06","2026-04-02","2026-04-02 (statement date in filing)","2026-04-06 (signature date)","2023-11-13","2009-01-09"],"entities":[{"asset_class":"equity","name":"Cartesian Therapeutics, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"equity","name":"Murat Kalayoglu","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Trust for the benefit of Murat Kalayoglu\u2019s spouse and children","relevance":"high","symbol":"","type":"trust"}],"event_type":"listing","information_gaps":["The signal text does not clearly specify the exact number of preferred shares converted beyond the numeric values shown in the filing; mapping each numeric value to \u201cbefore/after\u201d beneficial ownership is not fully explicit in the provided cleaned text.","The filing excerpt does not provide the prior known state (e.g., previous holdings immediately before this Form 4) needed to quantify the delta versus the last reported beneficial ownership.","No explicit guidance/financial implication (e.g., impact on earnings, liquidity, or share count) is stated in the provided text beyond the conversion event."],"key_facts":["SEC filing type: Form 4 (Statement of Changes in Beneficial Ownership of Securities).","Issuer: Cartesian Therapeutics, Inc.","Reporting owner: Murat Kalayoglu.","Filing date (as of date): 2026-04-06; period of report/conformed period: 2026-04-02.","Transaction described: On April 2, 2026, a trust elected to convert a portion of its shares of the issuer\u2019s Series A Non-Voting Convertible Preferred Stock into shares of the issuer\u2019s common stock.","The filing states remaining Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.","The filing states the securities represent merger consideration payable as a result of the issuer\u2019s November 13, 2023 acquisition/merger and securities purchased in a private placement in November 2023.","The spouse is a trustee of the Trust."],"numeric_claims":[{"label":"Conversion date","value":"2026-04-02"},{"label":"Preferred shares converted (as shown in filing values)","value":"22740.03"},{"label":"Common stock shares (as shown in filing values)","value":"33662.224"},{"label":"Common stock shares (as shown in filing values)","value":"758001"},{"label":"Common stock shares (as shown in filing values)","value":"506999"},{"label":"Series A Non-Voting Convertible Preferred Stock shares (as shown in filing values)","value":"5313261"},{"label":"Series A Non-Voting Convertible Preferred Stock shares (as shown in filing values)","value":"22740.03"}],"primary_claim":"On April 2, 2026, the Trust elected to convert a portion of its Cartesian Therapeutics Series A Non-Voting Convertible Preferred Stock into Cartesian Therapeutics common stock, with remaining preferred shares subject to a beneficial ownership limitation.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Cartesian Therapeutics, Inc. Form 4 was filed showing that on April 2, 2026, a trust for the reporting person\u2019s spouse and children converted a portion of its Series A Non-Voting Convertible Preferred Stock into the issuer\u2019s common stock. The filing also states these securities relate to merger consideration and a private placement from November 2023.","topics":["SEC Form 4","beneficial ownership","conversion of preferred to common","Series A Non-Voting Convertible Preferred Stock","common stock","merger consideration","private placement"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Cartesian Therapeutics, Inc. \u00b7 Filed 20260406","ticker":"RNAC","tickers":["RNAC"],"title":"RNAC filed 4","url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000148.txt"}}... |